Suzhou Zelgen Biopharmaceuticals

688266 · SSE STAR Market

Public Market Listing

688266SSE STAR Market

SSE STAR Market primary exchange listing

Live quotes, historical charts, and market capitalization for Suzhou Zelgen Biopharmaceuticals are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(2 total)
2Total Assets
0Approved
2Phase 3 / Filed
0Phase 1–2 / Early
5Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
jaktinib(Zepuping)
Phase 3
JAK1/2/3Small molecule
Atopic DermatitisMyelofibrosisAlopecia Areata
Phase 3
PD-1 and TIGITBiologic (subtype unspecified)
Non-Small Cell Lung CancerHepatocellular Carcinoma

Upcoming events

(10 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (8)
April 2027 (2)
Est. primary completion 2027-04 · NCT06883526 · CT.gov ↗
What to watch
jaktinib · Zepuping + NilvanstomigPhase 1/2Non-small Cell Lung Cancer
Est. primary completion 2027-04 · NCT06903377 · CT.gov ↗
What to watch
May 2027 (2)
NilvanstomigPhase 1/2Advanced Solid Tumor
Est. primary completion 2027-05 · NCT06938880 · CT.gov ↗
What to watch
NilvanstomigPhase 2Advanced Solid Tumor
Est. primary completion 2027-05 · NCT06927687 · CT.gov ↗
What to watch
August 2027 (1)
jaktinib · Zepuping + NilvanstomigPhase 1/2Cervical Cancer
Est. primary completion 2027-08 · NCT07080216 · CT.gov ↗
What to watch
September 2027 (1)
NilvanstomigPhase 1/2Small Cell Lung Cancer, Neuroendocrine Carcinoma
Est. primary completion 2027-09 · NCT07038096 · CT.gov ↗
What to watch
October 2027 (1)
jaktinib · Zepuping + NilvanstomigPhase 1/2Advanced Solid Tumor
Est. primary completion 2027-10 · NCT07142837 · CT.gov ↗
What to watch
December 2027 (1)
NilvanstomigPhase 2Biliary Tract Carcinoma
Est. primary completion 2027-12 · NCT07099547 · CT.gov ↗
What to watch
2031 (2)
September 2031 (1)
NilvanstomigPhase 3Hepatocellular Carcinoma
Est. primary completion 2031-09 · NCT07813572 · CT.gov ↗
What to watch
October 2031 (1)
NilvanstomigPhase 3Neuroendocrine Carcinomas (NEC)
Est. primary completion 2031-10 · NCT07833839 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

13 April 2026Topline resultjaktinibZGJAK025 (NCT05526222) Phase 3 in moderate-to-severe atopic dermatitis met its primary endpoints
Suzhou Zelgen Biopharmaceuticals Co., Ltd. · Source ↗
21 October 2025Topline resultjaktinibZGJAK029 (NCT05861102) Phase 3 in active ankylosing spondylitis met its primary endpoint
苏州泽璟生物制药股份有限公司 (Suzhou Zelgen Biopharmaceuticals Co., Ltd.) · Source ↗
13 June 2024Topline resultjaktinibZGJAK018 (NCT05051761) Phase 3 in severe alopecia areata met its primary endpoint
苏州泽璟生物制药股份有限公司 (Suzhou Zelgen Biopharmaceuticals Co., Ltd.) · Source ↗

Financial reports

Annual history (2 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$113M$60M$18M—report ↗
View 1 more year
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$74M$54M$30M—report ↗